Table S3.
Univariate analysis of PcG protein expression on prognosis of patients with ovarian serous cystadenocarcinoma (log-rank test)
| PcG protein expression levels in different tumor samples | Number of cases | Progression-free survival, months | P-value | Overall survival, months | P-value |
|---|---|---|---|---|---|
| BMI1 | |||||
| Primary | |||||
| Low | 63 | 34.4 | 0.529 | 89.6 | 0.668 |
| Intensive | 37 | 33.2 | 88.6 | ||
| Abdominal | |||||
| Low | 60 | 33.6 | 0.998 | 101.1 | 0.154 |
| Intensive | 40 | 33.9 | 82.7 | ||
| Lymph node | |||||
| Low | 19 | 37.2 | 0.010 | 99.8 | 0.330 |
| Intensive | 20 | 20.7 | 83.1 | ||
| Recurrent | |||||
| Low | 19 | 25 | 0.707 | 101.6 | 0.042 |
| Intensive | 32 | 27.8 | 65.7 | ||
| EZH2 | |||||
| Primary | |||||
| Low | 70 | 34.3 | 0.899 | 89.5 | 0.206 |
| Intensive | 30 | 31.3 | 86.7 | ||
| Abdominal | |||||
| Low | 63 | 36.9 | 0.282 | 90.5 | 0.763 |
| Intensive | 37 | 27.5 | 88.9 | ||
| Lymph node | |||||
| Low | 18 | 36.5 | 0.019 | 89.4 | 0.350 |
| Intensive | 21 | 23 | 88.2 | ||
| Recurrent | |||||
| Low | 21 | 31.2 | 0.195 | 93.2 | 0.047 |
| Intensive | 30 | 25.6 | 68.9 | ||
| RING1 | |||||
| Primary | |||||
| Low | 85 | 35.2 | 0.369 | 91.7 | 0.452 |
| Intensive | 15 | 26.5 | 88.5 | ||
| Abdominal | |||||
| Low | 86 | 36.2 | 0.057 | 89.1 | 0.418 |
| Intensive | 14 | 27.6 | 86.1 | ||
| Lymph node | |||||
| Low | 33 | 30.6 | 0.465 | 93.3 | 0.447 |
| Intensive | 6 | 22.7 | 87.2 | ||
| Recurrent | |||||
| Low | 30 | 32.5 | 0.154 | 99.3 | 0.205 |
| Intensive | 21 | 26.8 | 81.6 | ||
| RING2 | |||||
| Primary | |||||
| Low | 83 | 34.8 | 0.673 | 92.9 | 0.186 |
| Intensive | 17 | 23.8 | 74.1 | ||
| Abdominal | |||||
| Low | 84 | 33.9 | 0.798 | 94.6 | 0.330 |
| Intensive | 16 | 32.1 | 85.4 | ||
| Lymph node | |||||
| Low | 35 | 28.3 | 0.760 | 118.6 | 0.426 |
| Intensive | 4 | 32 | 98.2 | ||
| Recurrent | |||||
| Low | 34 | 27.2 | 0.706 | 90.5 | 0.546 |
| Intensive | 17 | 25.9 | 88.9 | ||
| CBX2 | |||||
| Primary | |||||
| Low | 83 | 35.5 | 0.272 | 92.8 | 0.186 |
| Intensive | 17 | 28.8 | 73.5 | ||
| Abdominal | |||||
| Low | 82 | 36.2 | 0.053 | 83.7 | 0.055 |
| Intensive | 18 | 25.7 | 68.4 | ||
| Lymph node | |||||
| Low | 34 | 30.9 | 0.066 | 100.8 | 0.280 |
| Intensive | 5 | 21.8 | 84.1 | ||
| Recurrent | |||||
| Low | 42 | 26.4 | 0.987 | 91.2 | 0.695 |
| Intensive | 9 | 28.4 | 81.9 | ||
| CBX4 | |||||
| Primary | |||||
| Low | 75 | 34.2 | 0.839 | 108.5 | 0.099 |
| Intensive | 25 | 33.5 | 82.6 | ||
| Abdominal | |||||
| Low | 75 | 36.5 | 0.252 | 96.9 | 0.386 |
| Intensive | 25 | 28.1 | 86.6 | ||
| Lymph node | |||||
| Low | 31 | 29.7 | 0.539 | 101.8 | 0.611 |
| Intensive | 8 | 25.6 | 90.4 | ||
| Recurrent | |||||
| Low | 31 | 29.2 | 0.629 | 97.7 | 0.285 |
| Intensive | 20 | 25.2 | 83.8 | ||
| PHF1 | |||||
| Primary | |||||
| Low | 70 | 34 | 0.954 | 104.4 | 0.113 |
| Intensive | 30 | 34.9 | 83.1 | ||
| Abdominal | |||||
| Low | 70 | 35.6 | 0.421 | 91.4 | 0.314 |
| Intensive | 30 | 32.4 | 86.1 | ||
| Lymph node | |||||
| Low | 34 | 30 | 0.754 | 60.8 | 0.429 |
| Intensive | 5 | 21 | 28.6 | ||
| Recurrent | |||||
| Low | 30 | 29.4 | 0.544 | 114.7 | 0.010 |
| Intensive | 21 | 24.9 | 73.8 | ||
Abbreviation: PcG, polycomb group.